Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, HC Wainwright Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective increased by analysts at HC Wainwright from $15.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 30.77% from the company’s previous close.

Separately, Craig Hallum upped their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Trading Down 9.2 %

Shares of NASDAQ:ETON opened at $13.00 on Monday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The stock has a market cap of $338.66 million, a P/E ratio of -59.09 and a beta of 1.38. The company has a 50 day moving average of $11.36 and a 200 day moving average of $7.16.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $54,000. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $90,000. Renaissance Technologies LLC raised its holdings in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter worth $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the period. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.